Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% below its 5-year average of 24.23%, near the low end of its 5-year range (-94.47%–845.45%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
21.23%
GROSS MARGIN AVG 5Y
24.23%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
43.54%
median of 609 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Amylyx Pharmaceuticals, Inc.
Market Cap
$3.03B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
21.23%
5Y Avg
24.23%
Market Cap
$3.03B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
50.00%
5Y Avg
66.67%
Market Cap
$3.05B
Gross Margin
91.14%
TTM Avg
90.25%
3Y Avg
87.92%
5Y Avg
58.61%
Market Cap
$2.97B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.82B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.79B
Gross Margin
58.69%
TTM Avg
59.64%
3Y Avg
63.22%
5Y Avg
64.62%
Market Cap
$2.71B
Gross Margin
46.93%
TTM Avg
47.02%
3Y Avg
48.36%
5Y Avg
47.58%
Market Cap
$2.69B
Gross Margin
31.95%
TTM Avg
33.09%
3Y Avg
31.97%
5Y Avg
31.83%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | $3.03B | 0.00% | 0.00% | 21.23% | 24.23% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.03B | 0.00% | 0.00% | 50.00% | 66.67% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.05B | 91.14% | 90.25% | 87.92% | 58.61% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $2.97B | 0.00% | 0.00% | 0.00% | 0.00% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.82B | 0.00% | 0.00% | 0.00% | 0.00% |
| TransMedics Group, Inc. (TMDX)vs › | $2.79B | 58.69% | 59.64% | 63.22% | 64.62% |
| AtriCure, Inc. (ATRC)vs › | $2.78B | 76.16% | 74.55% | 74.69% | 74.35% |
| Neogen Corporation (NEOG)vs › | $2.71B | 46.93% | 47.02% | 48.36% | 47.58% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 31.95% | 33.09% | 31.97% | 31.83% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | 17.61% | 20.09% | 39.91% | 58.59% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | -94.47% |
| 2024-06-30 | 845.45% |
| 2024-03-31 | -31.32% |
| 2023-12-31 | 91.37% |
| 2023-09-30 | 94.92% |
| 2023-06-30 | 94.32% |
| 2023-03-31 | 92.60% |
| 2022-12-31 | 87.11% |
| 2022-09-30 | 50.14% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
